Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Summary

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.

Timeline

Start

2021-06-08

Primary completion

2026-04

Completion

2026-06

Drugs

Indications